Orchid mulls product buys, returns to 3Q profit on API growth
This article was originally published in Scrip
Executive Summary
Orchid Chemicals & Pharmaceuticals plans to acquire a clutch of products in the US and the EU this year to build its brand portfolio, even as gains from its supply arrangement for active pharmaceutical ingredients (APIs) to Hospira of the US lifted profits in the third quarter.